Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

EuroEyes International Eye Clinic Limited
德視佳國際眼科有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1846)

(1) RESIGNATION OF CHIEF FINANCIAL OFFICER; (2) REDESIGNATION OF DIRECTOR; (3) APPOINTMENT OF CHIEF FINANCIAL OFFICER AND EXECUTIVE DIRECTOR; AND (4) CHANGE OF LISTING RULES AUTHORISED REPRESENTATIVE

RESIGNATION OF CHIEF FINANCIAL OFFICER

The board (the "**Board**") of directors (the "**Director(s)**") of EuroEyes International Eye Clinic Limited (the "**Company**") hereby announces that Mr. Marcus Huascar Bracklo ("**Mr. Bracklo**") has tendered his resignation as the chief financial officer of the Company ("**CFO**") and will cease to act as the authorised representative of the Company (the "**LR Authorised Representative**") for the purpose of Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") with effect from 31 October 2026 due to his own plan of career development (collectively, the "**Resignation**").

Mr. Bracklo has confirmed that he has no disagreement with the Board and there are no other matters in relation to the Resignation that need to be brought to the attention of the shareholders of the Company (the "**Shareholders**") or The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

REDESIGNATION OF DIRECTOR

The Board hereby announces that Mr. Bracklo has resigned as an executive Director with effect from 31 October 2026 and has been redesignated to a non-executive Director with effect from 1 November 2026 due to his own plan of career development.

The biographical details of Mr. Bracklo are as follows:

Mr. Bracklo, aged 62, is a strategic advisor of the Company. Having first joined the Group in July 2012, he is primarily responsible for advising on its strategy and business development. Mr. Bracklo was appointed as a non-executive Director in March 2019, redesignated as an executive Director, and appointed as the CFO in September 2025. He also served as a member of the audit committee of the Board from October 2019 to September 2025.

Mr. Bracklo has over 25 years of experience in the healthcare sector, specialising in corporate finance, accounting and mergers and acquisitions. From October 1987 to August 1998, he worked at Price Waterhouse, currently known as PricewaterhouseCoopers and was admitted to partnership in June 1997. In October 1998, he was admitted to the partnership of Arthur Andersen as their head of healthcare in Europe during which he was primarily responsible for cross-border mergers and acquisitions in the healthcare industry. From December 2001 to September 2007, he was a managing director of the investment bank, Sal. Oppenheim. Jr. & Cie. AG & Co. KgaA and a member of their investment banking committee where he was primarily responsible for their investment banking business in the healthcare industry. He is a director of Baigo Capital GmbH, an advisory and investment firm specialising in the healthcare sector, which he founded in October 2008. He has also served as a non-executive chairman of Lohfert & Lohfert AG, a healthcare consultancy firm since January 2020.

Mr. Bracklo obtained his bachelor's degree in Economic Science from the University College London, the United Kingdom (the "**UK**") in August 1986. He obtained his master's degree in Economic Science from the London School of Economics, the UK in November 1987. He became a chartered accountant in the UK in 1990 and was appointed a public auditor (Wirtschaftsprüfer) in Germany in January 1995.

A letter of appointment was entered into between the Company and Mr. Bracklo pursuant to which he was appointed as a non-executive Director for a term of two (2) years. Mr. Bracklo will be subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the requirements of the articles of the association of the Company (the "**Articles**"). Mr. Bracklo will be entitled to an emolument of HKD360,000 per annum as a non-executive Director, with reference to his duties and responsibilities with the Company and the prevailing market conditions and practice.

As at the date of this announcement and within the meaning of Part XV of the Securities and Futures Ordinance (Cap.571) (the "**SFO**"), Mr. Bracklo was deemed to be interested in 1,331,510 shares of the Company (which comprised 273,000 shares of the Company held in his personal capacity and 1,058,510 shares of the Company held by Baigo Capital GmbH, a company wholly owned by Mr. Bracklo), representing approximately 0.42% of the issued share capital of the Company.

Save as disclosed above, as at the date of this announcement, Mr. Bracklo (i) does not hold any other position with the Company or other members of the Group; (ii) did not hold any other directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) does not have any other major appointments and professional qualifications; (iv) does not have any relationships with any Directors, senior management, substantial shareholders or controlling shareholders (within the meaning of the Listing Rules) of the Company; and (v) does not have any interests in the shares of the Company within the meaning of Part XV of the SFO.

Save as disclosed herein, there is no other information relating to the redesignation of Mr. Bracklo as a non-executive Director that shall be disclosed pursuant to Rule 13.51(2) of the Listing Rules nor any matters which need to be brought to the attention of the Shareholders as at the date of this announcement.

APPOINTMENT OF CHIEF FINANCIAL OFFICER AND EXECUTIVE DIRECTOR

The Board is pleased to announce that Mr. Markus Schröder ("**Mr. Schröder**") has been appointed as the CFO and an executive Director with effect from 1 November 2026.

The biographical details of Mr. Schröder are as follows:

Mr. Schröder, aged 48, is a licensed tax advisor, registered with the Hamburg Chamber of Tax Advisors since March 2009. He graduated with a diploma in Business Administration from the University of Hamburg, Germany in June 2005.

Mr. Schröder has extensive experience as a commercial managing director, chief financial officer and head of finance across various corporate groups in Germany. He is currently the commercial director, chief financial officer and in-house counsel and tax advisor of ISA-TRAESKO GmbH in Neumünster, Germany, a position he has held since September 2022. From July 2018 to January 2020, Mr. Schröder served as the commercial director, in-house counsel and tax adviser of ATH Altonaer Technologie Holding GmbH in Hamburg, Germany before being appointed as its commercial managing director from January 2020 to June 2022. Previously, from October 2011 to June 2018, he served as the commercial director of HEROSE GmbH Armaturen und Metalle in Bad Oldesloe, Germany.

A service agreement was entered into between the Company and Mr. Schröder pursuant to which he was appointed as an executive Director for a term of two (2) years. Mr. Schröder will be subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the requirements of the Articles. Mr. Schröder will be entitled to an emolument of HKD30,000 per month as an executive Director, with reference to his duties and responsibilities with the Company and the prevailing market conditions and practice.

Save as disclosed above, as at the date of this announcement, Mr. Schröder (i) does not hold any other position with the Company or other members of the Group; (ii) did not hold any other directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) does not have any other major appointments and professional qualifications; (iv) does not have any relationships with any Directors, senior management, substantial shareholders or controlling shareholders (within the meaning of the Listing Rules) of the Company; and (v) does not have any interests in the shares of the Company within the meaning of Part XV of the SFO.

Save as disclosed herein, there is no other information relating to the appointment of Mr. Schröder as an executive Director that shall be disclosed pursuant to Rule 13.51(2) of the Listing Rules nor any matters which need to be brought to the attention of the Shareholders as at the date of this announcement.

CHANGE OF LISTING RULES AUTHORISED REPRESENTATIVE

The Board announces that with effect from 1 November 2026, Mr. Schröder, has been appointed as the LR Authorised Representative to fill up the vacancy of Mr. Bracklo.

The Board would like to take this opportunity to welcome Mr. Bracklo and Mr. Schröder in their new roles.

By Order of the Board
EuroEyes International Eye Clinic Limited
Dr. Jørn Slot Jørgensen
Chairman and Executive Director

Hong Kong, 30 October 2026

As at the date of this announcement, the Board comprises Dr. Jørn Slot Jørgensen, Mr. Jannik Jonas Slot Jørgensen, Professor Dan Zoltan Reinstein, Mr. Marcus Huascar Bracklo and Mr. Rens Laurentius Michaël Schoenmakers as executive Directors; Mr. Hans Helmuth Hennig, Ms. Katherine Rong Xin and Mr. Philip Duncan Wright as independent non-executive Directors.